ReviewFrontiers in microbiology2021
Key Technologies for Progressing Discovery of Microbiome-Based Medicines.
Review in Frontiers in microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Multi-Omics-Driven Insights into Cancer Biology and Therapeutic Targeting.AAPS PharmSciTech · 2026Review
- Quantitative evaluation of microbiome sequencing resolution under varying experimental conditions using defined mock communities.Scientific reports · 2026Article
- Gut-Microbiota-Derived Metabolites and Probiotic Strategies in Colorectal Cancer: Implications for Disease Modulation and Precision Therapy.Nutrients · 2025Review
- Age- and disease severity-associated changes in the nasopharyngeal microbiota of COVID-19 patients.iScience · 2025Article
- Live Biotherapeutic Products for Metabolic Diseases: Development Strategies, Challenges, and Future Directions.Journal of microbiology and biotechnology · 2025Review
- Advances in human microbiome and prostate cancer research.Frontiers in immunology · 2025Review
- Comparison of microbiome community structure and dynamics during anaerobic digestion of different renewable solid wastes.Current research in microbial sciences · 2025Article
- EVOLVING TRENDS AND EMERGING THEMES IN GUT MICROBIOTA RESEARCH: A COMPREHENSIVE BIBLIOMETRIC ANALYSIS (2015-2024).Arquivos de gastroenterologia · 2025Article
- Microbial Dynamics in COVID-19: Unraveling the Impact of Human Microbiome on Disease Susceptibility and Therapeutic Strategies.Current microbiology · 2024Review
- The nasopharyngeal microbiome in COVID-19.Emerging microbes & infections · 2023Article
- ReducingAnalytical chemistry · 2023Article
- Gut microbiome signatures of Yorkshire Terrier enteropathy during disease and remission.Scientific reports · 2023Article
- Effect of aNutrients · 2022Article
- Efficient and Quality-Optimized Metagenomic Pipeline Designed for Taxonomic Classification in Routine Microbiological Clinical Tests.Microorganisms · 2022Article
- Emerging microfluidic technologies for microbiome research.Frontiers in microbiology · 2022Review
- The Interaction among Microbiota, Epigenetic Regulation, and Air Pollutants in Disease Prevention.Journal of personalized medicine · 2021Review
- Mining the Microbiome and Microbiota-Derived Molecules in Inflammatory Bowel Disease.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A growing number of experimental and computational approaches are illuminating the "microbial dark matter" and uncovering the integral role of commensal microbes in human health. Through this work, it is now clear that the human microbiome presents great potential as a therapeutic target for a plethora of diseases, including inflammatory bowel disease, diabetes and obesity. The development of more efficacious and targeted treatments relies on identification of causal links between the microbiome and disease; with future progress dependent on effective links between state-of-the-art sequencing approaches, computational analyses and experimental assays. We argue determining causation is essential, which can be attained by generating hypotheses using multi-omic functional analyses and validating these hypotheses in complex, biologically relevant experimental models. In this review we discuss existing analysis and validation methods, and propose best-practice approaches required to enable the next phase of microbiome research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.